Immunomodulatory therapies for sepsis: unexpected effects with macrolides

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 1, 2008, Pages

  Giamarellos Bourboulis, Evangelos J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clarithromycin; Immunomodulation; Sepsis

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM; CLARITHROMYCIN; DROTRECOGIN; ENDOTOXIN ANTIBODY; ERYTHROMYCIN; ETANERCEPT; HYDROCORTISONE; IMMUNOMODULATING AGENT; INSULIN; LENERCEPT; MACROLIDE; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ADRENAL INSUFFICIENCY; ARTICLE; BRONCHIOLITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; LOW DRUG DOSE; LUNG FIBROSIS; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NONHUMAN; PANBRONCHIOLITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MACROLIDES; SEPSIS;

EID: 53849142125     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.004     Document Type: Article

References (32)

1. Heron M. Deaths: leading causes for 2004. Natl Vital Stat Rep 56 (2007) 1-95
2. Engel C., Brunkhorst F.M., Bone H.G., Brunkhorst R., Gerlach H., Grond S., et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33 (2007) 606-618
3. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 (2008) 296-327
4. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003) 138-150
5. Vincent J.L., Sun Q., and Dubois M.J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34 (2003) 1084-1093
6. Bone R.C., Balk R.A., Fein A.M., Perl T.M., Wenzel R.P., Reines H.D., et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 23 (1995) 994-1006
7. Rice T.W., Wheeler A.P., Morris P.E., Paz H.L., Russell J.A., Edens T.R., et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine Fab for injection (CytoFab) in severe sepsis. Crit Care Med 34 (2006) 2271-2281
8. Reinhart K., Wiegand-Löhnert C., Grimminger F., Kaul M., Withington S., Treacher D., et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24 (1996) 733-742
9. Cohen J., and Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24 (1996) 1431-1440
10. Abraham E., Laterre P.F., Garbino J., Pingleton S., Butler T., Dugernier T., et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 29 (2001) 503-510
11. Abraham E., Glauser M.P., Butler T., Garbino J., Gelmont D., Laterre P.F., et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277 (1997) 1531-1538
12. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
13. Abraham E., Laterre P.F., Garg R., Levy H., Talwar D., Trzaskoma B.L., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 (2005) 1332-1341
14. Brunkhorst F.M., Engel C., Bloos F., Meier-Hellmann A., Ragaller M., Weiler N., et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358 (2008) 125-139
15. Annane D., Sébille V., Charpentier C., Bollaert P.E., François B., Korach J.M., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
16. Sprung C.L., Annane D., Keh D., Moreno R., Singer M., Freivogel K., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 (2008) 111-124
17. Kadota J., Mukae H., Ishii H., Nagata T., Kaida H., Tomono K., et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 97 (2003) 844-850
18. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 54 (2005) 21-28
19. Giamarellos-Bourboulis E.J. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 31 (2008) 12-20
20. Kikuchi T., Hagiwara K., Honda Y., Gomi K., Kobayashi T., Takahashi H., et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 49 (2002) 745-755
21. García Vázquez E., Mensa J., Martínez J.A., Marcos M.A., Puig J., Ortega M., et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 24 (2005) 190-195
22. Martínez J.A., Horcajada J.P., Almela M., Marco F., Soriano A., García E., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36 (2003) 389-395
23. Metersky M.L., Ma A., Houck P.M., and Bratzler D.W. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 131 (2007) 466-473
24. Giamarellos-Bourboulis E.J., Adamis T., Laoutaris G., Sabracos L., Koussoulas V., Mouktaroudi M., et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 48 (2004) 93-99
25. Giamarellos-Bourboulis E.J., Antonopoulou A., Raftogiannis M., Koutoukas P., Tsaganos T., Tziortzioti V., et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 6 (2006) 31
26. Giamarellos-Bourboulis E.J., Baziaka F., Antonopoulou A., Koutoukas P., Kousoulas V., Sabracos L., et al. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli. Int J Antimicrob Agents 25 (2005) 168-172
27. Giamarellos-Bourboulis E.J., Adamis T., Sabracos L., Raftogiannis M., Baziaka F., Tsaganos T., et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 37 (2005) 48-54
28. Giamarellos-Bourboulis E.J., Tziortzioti V., Koutoukas P., Baziaka F., Raftogiannis M., Antonopoulou A., et al. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 57 (2006) 937-944
29. Baziaka F., Giamarellos-Bourboulis E.J., Raftogiannis M., Adamis T., Tziortzioti V., Sabracos L., et al. Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa. J Chemother 20 (2008) 63-68
30. Abbott Laboratories. Clarithromycin for intravenous injection. Clinical expert report. Data on file; December 1998.
31. Levy M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31 (2003) 1250-1256
32. Giamarellos-Bourboulis E.J., Pechère J.C., Routsi C., Plachouras D., Kollias S., Raftogiannis M., et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46 (2008) 1157-1164